Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients' and professionals' expertise - A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative

European Journal of Cancer

Volumn 51, Issue 2, 2015, Pages 127-136

  Kasper, B ^a   Baumgarten, C ^b   Bonvalot, S ^b   Haas, R ^c   Haller, F ^d   Hohenberger, P ^a   Moreau, G ^e   Van Der Graaf, W T A ^f   Gronchi, A ^g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SPAEN Sarcoma Patients EuroNet EV ^*  (France)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e SOS Desmoide   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Consensus; Desmoid type fibromatosis; EORTC STBSG; Patient advocacy groups; SPAEN; Treatment algorithm

Indexed keywords

ANTHRACYCLINE; APC; CATENIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IMATINIB; METHOTREXATE; METHOTREXATE PLUS VINBLASTINE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAZOPANIB; SORAFENIB; SULINDAC; SUNITINIB; TAMOXIFEN; UNCLASSIFIED DRUG; VINBLASTINE;

ALGORITHM; ANALGESIA; ARTICLE; BIOPSY; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CONSENSUS; CONSENSUS DEVELOPMENT; CONTRAST ENHANCEMENT; CRYOABLATION; DESMOID FIBROMATOSIS; DIFFERENTIAL DIAGNOSIS; DRUG MONITORING; EUROPEAN; EVIDENCE BASED MEDICINE; FIBROMATOSIS; GENE MUTATION; HORMONAL THERAPY; HUMAN; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT ADVOCACY; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL SUPPORT; SYSTEMIC THERAPY; TREATMENT DURATION; BONE NEOPLASMS; EUROPE; FIBROMATOSIS, AGGRESSIVE; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; OSTEOSARCOMA; PATIENT CARE; PROCEDURES; SARCOMA;

ALGORITHMS; BIOMEDICAL RESEARCH; BONE NEOPLASMS; EUROPE; FIBROMATOSIS, AGGRESSIVE; HUMANS; OSTEOSARCOMA; PATIENT CARE MANAGEMENT; SARCOMA;

EID: 84925397102     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.11.005     Document Type: Article

References (40)

1. B. Kasper, P. Stroebel, and P. Hohenberger Desmoid tumors - clinical features and treatment options for advanced disease Oncologist 16 2011 682 693
2. W.L. Wang, C. Nero, A. Pappo, D. Lev, A.J. Lazar, and D. López-Terrada CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm Pediatr Dev Pathol 15 2012 361 367
3. A. Gronchi, C. Colombo, C. Le Pechoux, A.P. Dei Tos, A. Le Cesne, and A. Marrari Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasing neoplasm - position paper from the Italian and French Sarcoma Group Ann Oncol 25 2014 578 583
4. S. Le Guellec, I. Soubeyran, P. Rochaix, T. Filleron, A. Neuville, and I. Hostein CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics Mol Pathol 25 2012 1551 1558
5. A.J. Lazar, D. Tuvin, S. Hajibashi, S. Habeeb, S. Bolshakov, and E. Mayordomo-Aranda Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors Am J Pathol 173 2008 1518 1527
6. C. Colombo, R. Miceli, A.J. Lazar, F. Perrone, R.E. Pollock, and A. Le Cesne CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study Cancer 119 2013 3696 3702
7. J. Dômont, S. Salas, L. Lacroix, V. Brouste, P. Saulnier, and P. Terrier High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management Br J Cancer 102 2010 1032 1036
8. J.T. Mullen, T.F. DeLaney, A.E. Rosenberg, L. Le, A.J. Iafrate, and W. Kobayashi β-Catenin mutation status and outcomes in sporadic desmoid tumors Oncologist 18 2013 1043 1049
9. G. Castellazzi, D. Vanel, A. Le Cesne, C. Le Pechoux, H. Caillet, and F. Perona Can the MRI signal of aggressive fibromatosis be used to predict its behaviour? Eur J Radiol 69 2009 222 229
10. B. Kasper, A. Dimitrakopoulou-Strauss, L.G. Strauss, and P. Hohenberger Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib Eur J Nucl Med Mol Imag 37 2010 1876 1882
11. A. Dimitrakopoulou-Strauss, P. Hohenberger, L. Pan, B. Kasper, S. Roumia, and L.G. Strauss Dynamic PET with FDG in patients with unresectable aggressive fibromatosis: regression-based parametric images and correlation to the FDG kinetics based on a 2-tissue compartment model Clin Nucl Med 37 2012 943 948
12. B. Kasper, A. Dimitrakopoulou-Strauss, L.R. Pilz, L.G. Strauss, C. Sachpekidis, and P. Hohenberger Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib Biomed Res Int 2013 2013 7 10.1155/2013/389672 [Article ID 389672]
13. C.S. Trovik, H.C.F. Bauer, T.A. Alvegard, H. Anderson, C. Blomqvist, and O. Berlin Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 599 surgically-treated patients from the Scandinavian Sarcoma Group register Eur J Cancer 36 2000 710 716
14. A. Stojadinovic, D.H. Leung, A. Hoos, D.P. Jaques, J.J. Lewis, and M.F. Brennan Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas Ann Surg 235 2002 424 434
15. G.K. Zagars, M.T. Ballo, P.W. Pisters, R.E. Pollock, S.R. Patel, and R.S. Benjamin Surgical margins and re-excision in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy Cancer 97 2003 2530 2543
16. A. Gronchi, S. Lo Vullo, C. Colombo, P. Collini, S. Stacchiotti, and L. Mariani Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival Ann Surg 251 2010 512 517
17. A. Gronchi, P.G. Casali, L. Mariani, S. Lo Vullo, M. Colecchia, and L. Lozza Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution J Clin Oncol 21 2003 1390 1397
18. D. Lev, D. Kotilingam, C. Wei, M.T. Ballo, G.K. Zagars, and P.W. Pisters Optimizing treatment of desmoid tumors J Clin Oncol 25 2007 1785 1791
19. S. Salas, A. Dufresne, B. Bui, J.Y. Blay, P. Terrier, and D. Ranchere-Vince Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation J Clin Oncol 29 2011 3553 3558
20. S. Bonvalot, H. Eldweny, V. Haddad, F. Rimareix, G. Missenard, and O. Oberlin Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients Eur J Surg Oncol 34 2008 462 468
21. J.J. Lewis, P.J. Boland, D.H. Leung, J.M. Woodruff, and M.F. Brennan The enigma of desmoid tumors Ann Surg 229 1999 866 872
22. M. Fiore, F. Rimareix, L. Mariani, J. Domont, P. Collini, and C. Le Péchoux Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment Ann Surg Oncol 16 2009 2587 2593
23. S. Briand, O. Barbier, D. Biau, A. Bertrand-Vasseur, F. Larousserie, and P. Anract Wait-and-See policy as a first-line management for extra-abdominal desmoid tumors J Bone Joint Surg Am 96 2014 631 638
24. S. Bonvalot, N. Ternes, M. Fiore, G. Bitsakou, C. Colombo, and C. Honoré Spontaneous regression of primary abdominal wall desmoids: more common than previously thought Ann Surg Oncol 20 2013 4096 4102
25. S. Bonvalot, F. Rimareix, S. Causeret, C. Le Péchoux, B. Boulet, and P. Terrier Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient Ann Surg Oncol 16 2009 3350 3357
26. J.L. Kujak, P.T. Liu, G.B. Johnson, and M.R. Callstrom Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors Skeletal Radiol 39 2010 175 182
27. < http://www.nccn.org/professionals/physician-gls/pdf/sarcoma.pdf > version, 1; 2013.
28. ESMO/European Sarcoma Network Working Group Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 Suppl. 3 2014 iii102 iii112
29. B.A. Guadagnolo, G.K. Zagars, and M.T. Ballo Long-term outcomes for desmoid tumors treated with radiation therapy Int J Radiat Oncol Biol Phys 71 2008 441 447
30. R.B. Keus, R.A. Nout, J.Y. Blay, J.M. de Jong, I. Hennig, and F. Saran Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis - an EORTC STBSG and ROG study (EORTC 62991-22998) Ann Oncol 24 2013 2672 2676
31. J. Janinis, M. Patriki, L. Vini, G. Aravantinos, and J.S. Whelan The pharmacological treatment of aggressive fibromatosis: a systematic review Ann Oncol 14 2003 181 190
32. S.X. Skapek, J.R. Anderson, D.A. Hill, D. Henry, S.L. Spunt, and W. Meyer Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a children's oncology group (COG) phase II study Pediatr Blood Cancer 60 2013 1108 1112
33. S.X. Skapek, W.S. Ferguson, L. Granowetter, M. Devidas, A.R. Perez-Atayde, and L.P. Dehner Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial J Clin Oncol 25 2007 501 506
34. D. Garbay, A. Le Cesne, N. Penel, C. Chevreau, P. Marec-Berard, and J.Y. Blay Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG) Ann Oncol 23 2012 182 186
35. A. Constantinidou, R.L. Jones, M. Scurr, O. Al-Muderis, and I. Judson Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis Eur J Cancer 45 2009 2930 2934
36. M.C. Heinrich, G.A. McArthur, G.D. Demetri, H. Joensuu, P. Bono, and R. Herrmann Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour) J Clin Oncol 24 2006 1195 1203
37. N. Penel, A. Le Cesne, B.N. Bui, D. Perol, E.G. Brain, and I. Ray-Coquard Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up Ann Oncol 22 2011 452 457
38. B. Kasper, V. Grünwald, P. Reichardt, S. Bauer, G. Rauch, and M. Sommer Phase II study evaluating imatinib to induce progression arrest in RECIST progressive desmoid tumors not amenable to surgical resection with R0 intent or accompanied by unacceptable function loss - a study of the German Interdisciplinary Sarcoma Group (GISG) Ann Oncol 25 Suppl. 4 2014 iv494
39. M.M. Gounder, R.A. Lefkowitz, M.L. Keohan, D.R. D'Adamo, M. Hameed, and C.R. Antonescu Activity of sorafenib against desmoid tumor/deep fibromatosis Clin Cancer Res 17 2011 4082 4090
40. M. Fiore, S. Coppola, A.J. Cannell, C. Colombo, M.M. Bertagnolli, and S. George Desmoid-type fibromatosis and pregnancy Ann Surg 259 2014 973 978